MLICM
CGEM icon

Metropolitan Life Insurance Company (MetLife)’s Cullinan Oncology CGEM Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,286
Closed -$21.9K – 410
2024
Q1 		$21.9K Hold
1,286
– – ﹤0.01% 1811
2023
Q4 		$13.1K Hold
1,286
– – ﹤0.01% 2085
2023
Q3 		$11.6K Hold
1,286
– – ﹤0.01% 2149
2023
Q2 		$13.8K Sell
1,286
-503
-28% -$5.34K ﹤0.01% 2122
2023
Q1 		$18.3K Sell
1,789
-197
-10% -$2.17K ﹤0.01% 1925
2022
Q4 		$21K Buy
1,986
+156
+9% +$1.9K ﹤0.01% 1984
2022
Q3 		$23.5K Hold
1,830
– – ﹤0.01% 1951
2022
Q2 		$23.5K Hold
1,830
– – ﹤0.01% 1967
2022
Q1 		$19.2K Sell
1,830
-5,590
-75% -$75.5K ﹤0.01% 2117
2021
Q4 		$114K Hold
7,420
– – ﹤0.01% 2395
2021
Q3 		$167K Buy
7,420
+2,418
+48% +$64.7K ﹤0.01% 2208
2021
Q2 		$129K Buy
5,002
+545
+12% +$16.8K ﹤0.01% 2454
2021
Q1 		$186K Buy
+4,457
New +$181K ﹤0.01% 2071

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CGEM Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Cullinan Oncology (CGEM) in Q2 2024, closing a stake of 1,286 shares — an estimated $21.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CGEM in Q1 2021 and held it in 13 quarters. The position peaked at $186K in Q1 2021. 135 funds tracked by Wall St. Rank hold CGEM as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Cullinan Oncology position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,286 Cullinan Oncology shares in Q2 2024, an estimated $21.9K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Cullinan Oncology in Q1 2021 and held it in 13 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Cullinan Oncology position peaked at $186K in Q1 2021.
  • 135 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.